Adam S. Grossman, President and CEO of ADMA Biologics (ADMA), has demonstrated a consistent pattern of selling activity in the company’s stock over the past year, with no recent purchases recorded in SEC filings. Since August 2025, Grossman has executed 13 sales totaling approximately $5.39 million, with the largest transactions occurring in early 2026. Notably, on March 6, 2026, he sold shares worth $868,580.82, followed by another $454,205.07 the next day, marking two of the highest-value disposals in this period. Smaller but repeated sales—often paired with option exercises (coded "M")—appear at regular intervals, such as the $241,200 and $96,480 transactions on February 17, 2026, and similar dispositions in prior months.
Grossman’s trading activity is concentrated solely in ADMA, with no diversification across other securities. The sales, often structured in clusters, suggest a methodical approach to reducing his position. While he has acquired shares in the past—evidenced by a lifetime buy total of $648,000—the recent absence of purchases and the scale of disposals indicate a clear directional shift. The transactions include a mix of open-market sales (code "S") and derivative-related activity, such as option exercises, which are typically tied to prearranged equity compensation plans. The pattern aligns with routine executive stock monetization rather than abrupt changes in exposure, though the consistent selling bias is notable.
AI-assisted summary